Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 2 of 22 for:    cantos

Breast Cancer Toxicity (CANTO)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2015 by UNICANCER
Information provided by (Responsible Party):
UNICANCER Identifier:
First received: October 17, 2013
Last updated: May 27, 2015
Last verified: May 2015

The aims of the cohort will be to quantify impact of cancer treatments toxicities , and to generate predictors of chronic toxicity in patients with non-metastatic breast cancer.

The project will include four specific aims :

  1. To develop a database of chronic treatment related toxicity in a cohort of 20 000 women with stage I-III breast cancer (= non metastatic), whatever these treatments are (surgery; radiation therapy; chemotherapy …)
  2. To describe incidence, clinical presentation, and outcome of chronic toxicities over a maximum of 8 years.
  3. To describe the psychological, the social and the economic impacts of chronic toxicities.
  4. To generate predictors for chronic toxicities in order to prevent them, based upon biological criteria.

The expected impact of these toxicities, when identified, will be to improve quality of life and to decrease health cost, by the early identification of patients at high risk of toxicity. Such early identification could lead to prevent toxic effect by: a. developing prevention strategies, b. substituting toxic treatment by a non (less) toxic one.

Also, such cohort will offer a quantification of the impact of treatment toxicity, that could be further used to quantify medical usefulness of strategies that aim at decreasing treatment toxicities (implementation of predictive biomarker for resistance, cytotoxic-free regimen etc…)

Condition Intervention
Breast Cancer Nos Metastatic Recurrent
Procedure: blood sampling

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer

Resource links provided by NLM:

Further study details as provided by UNICANCER:

Primary Outcome Measures:
  • Evaluation of chronic toxicity in patients treated for non-metastatic breast cancer [ Time Frame: 8 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 20000
Study Start Date: February 2012
Estimated Study Completion Date: March 2026
Estimated Primary Completion Date: March 2022 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
breast cancer treatment + blood sampling
Standard treatment of breast cancer with intervention : samples collection
Procedure: blood sampling
blood samples collection

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • women
  • Aged 18 years and over,
  • With an invasive breast cancer diagnosed by cytology or histology,
  • Tumors cT0 to cT3, CN0-3
  • No clinical evidence of metastasis at the time of inclusion,
  • Untreated including scored for breast cancer surgery in progress,
  • Patient receiving a social security system,
  • Patient mastering the French language,
  • Free and informed consent for additional biological samples, different questionnaires and collecting information on resource usage.

Exclusion Criteria:

  • Metastatic breast cancer,
  • Local recurrence of breast cancer,
  • History of cancer within 5 years prior to entry into the trial other than basal cell skin or carcinoma in situ of the cervix,
  • Already received treatment for breast cancer ongoing
  • Blood transfusion performed for less than six months,
  • Persons deprived of liberty or under supervision (including guardianship).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01993498

Contact: christel Mesleard (0)1 44 23 55 51 ext + 33
Contact: Anne Laure Martin (0)1 44 23 55 56

Gustave roussy Recruiting
Villejuif, France, 94805
Contact: Fabrice ANDRE    (0)1 42 11 43 71 ext +33      
Principal Investigator: Laetitia Shanna RAJPAR         
Principal Investigator: Patrick SOULIE         
Principal Investigator: Severine GUIU         
Principal Investigator: Laurence VANLEMMENS         
Principal Investigator: Marion FOURNIER         
Principal Investigator: Anne LESUR         
Principal Investigator: Olivier TREDAN         
Principal Investigator: Paul henri COTTU         
Principal Investigator: Christelle LEVY         
Principal Investigator: Mario CAMPONE         
Principal Investigator: Carole TARPIN         
Principal Investigator: Florence LEREBOURS         
Principal Investigator: Hervé CURE         
Principal Investigator: Marie Ange MOURET REYNIER         
Principal Investigator: Olivier RIGAL         
Principal Investigator: Jean Marc FERRERO         
Principal Investigator: Thierry PETIT         
Principal Investigator: Pierre KERBRAT         
Principal Investigator: Antoine ARNAUD         
Sponsors and Collaborators
Principal Investigator: Fabrice André Gustave Roussy - Villejuif
  More Information

Responsible Party: UNICANCER Identifier: NCT01993498     History of Changes
Other Study ID Numbers: UC 0140/1103 CANTO  2011-A01095-36 
Study First Received: October 17, 2013
Last Updated: May 27, 2015
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by UNICANCER:
cancer toxicities
breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases processed this record on October 27, 2016